Aclaris Therapeutics ACRS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Dermatology Therapeutics | $6.4M-58.6% | $5.95M-63.2% | $13.76M-44.1% | $14.64M-50.3% | $15.45M-45.4% | |
| Research And Development Project Spend by Product | ||||||
| Drug Candidate Ati052 | $9.64M+372% | $7.07M+273% | $4.35M— | $2.98M— | $2.04M— | |
| Drug Candidate Ati2138 | $3.6M-39.5% | $4.92M+16.9% | $7.04M+53.2% | $6.32M-8.2% | $5.96M-35.1% | |
| Drug Candidate Bosakitug | $13.6M+277% | $13.85M+4,530% | $9.37M— | $6.38M— | $3.61M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aclaris Therapeutics break its business down?
- Aclaris Therapeutics (ACRS) reports revenue by product across 2 parts — Contract Research and Dermatology Therapeutics. Each is extracted from the segment footnotes and tracked over time.
- Where does Aclaris Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aclaris Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
